Consensus Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
4.62 ^USD	+5.48%		+4.05%	-14.76%

May. 16	Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	MT
May. 15	Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Sagimet Biosciences Inc.

Price target over the last 5 years

History of analyst recommendation changes

a45108d7f83716fb20e7f550.1-a0zcZPotpvGSdkUN8K5qwI1LCFXQ6X7dxgY-N7EnU.rqrMl6E44JwaU3IXJPJDv-1lpYmwEiPE2rMUFoBNXBq_sYyFgQPDmxdbUA~4e3c46525648eac14e6c0279144231b8

Analyst Recommendations on Sagimet Biosciences Inc.

Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	May. 16	MT
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	May. 02	MT
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	Mar. 26	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	Mar. 25	MT
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	Feb. 07	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	Jan. 23	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	Jan. 23	MT
TD Cowen Initiates Sagimet Biosciences With Outperform Rating	23-08-08	MT
Goldman Sachs Initiates Sagimet Biosciences at Buy With $33 Price Target	23-08-08	MT
Piper Sandler Initiates Sagimet Biosciences With Overweight Rating, $67 Price Target	23-08-08	MT
JMP Securities Starts Sagimet Biosciences With Market Outperform Rating, $30 Price Target	23-08-08	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.62 USD

Average target price

39.2 USD

Spread / Average Target

+748.48%

High Price Target

67 USD

Spread / Highest target

+1,350.22%

Low Price Target

23 USD

Spread / Lowest Target

+397.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sagimet Biosciences Inc.

Goldman Sachs
HC Wainwright
Leerink Partners
JMP Securities
TD Cowen
Piper Sandler

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar